Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Hepatitis C virus infection. N Engl J Med (2001) 18.67

Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology (1997) 5.26

Evasion of intracellular host defence by hepatitis C virus. Nature (2005) 4.58

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ (2004) 4.22

The dsRNA protein kinase PKR: virus and cell control. Biochimie (2007) 3.67

Optimal therapy of hepatitis C. Hepatology (2002) 2.40

Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe (2009) 2.33

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology (2009) 2.21

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (2009) 2.07

Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol (2006) 1.84

Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ (2002) 1.71

Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev (2007) 1.65

Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Virol (2002) 1.22

Antigenic relevance of F protein in chronic hepatitis C virus infection. Hepatology (2004) 1.10

Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg (2002) 1.10

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther (2004) 1.08

Interferon regulatory factor 3-independent double-stranded RNA-induced inhibition of hepatitis C virus replicons in human embryonic kidney 293 cells. J Virol (2005) 0.92

Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR. Virus Res (2007) 0.91

Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients. Virol J (2011) 0.88

Hepatitis C virus expression and interferon antiviral action is dependent on PKR expression. J Med Virol (2007) 0.88

Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat (2007) 0.84

Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients. Intervirology (2008) 0.84

Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol (2010) 0.80